A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment-Nave Subjects with Acute Myelogenous Leukemia Who Are 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy
A study for patients with Acute Myelogenous Leukemia using study drug ABT-199
Sponsor: AbbVie Inc
Enrolling: Male and Female Patients
IRB Number: AAAO1055
U.S. Govt. ID: NCT02287233
Contact: Joseph Jurcic, MD: 212-851-4872 / jgj2110@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the safety, and effectiveness of ABT-199 in combination with decitabine and ABT-199 in combination with azacitidine in subjects who have not been treated for their AML. In addition, substances (biomarkers) found in the blood and bone marrow that may indicate the effects or progress of the leukemia and the activity of ABT-199 in combination with decitabine or azacitidine will be studied. Optional pharmacogenetics (genetic differences that can affect individual responses to ABT-199) will also be evaluated.
This study is closed
Investigator
Joseph Jurcic, MD
Do You Qualify?
Do you have a history of Acute Myelogenous Leukemia (AML)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Joseph Jurcic, MD
jgj2110@cumc.columbia.edu
212-851-4872
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE